To evaluate the feasibility of treating prehypertension with an angiotension receptor blocker candesartan Cilexetil. | [Pakistan Journal of Pharmacology • 2011]

Author(s):

1. Shah Nawaz Jamali: Department of Pharmacology, HCM & D, Hamdard University, Karachi, Pakistan

2. Muhammd Jamil Laghari: Department of Pharmacology and Therapeutics, LUMHS, Jamshoro, Pakistan

3. Mahay Rukh: Department of Pharmacology and Therapeutics, DMC & Civil Hospital, DUHMS, Karachi, Pakistan, Pakistan

4. Muhammad Arif: Department of Pharmacology, Baqai Medical University, Karachi, Pakistan

Abstract:

Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk. The trial of preventing hypertension (TROPHY) was an investigator-initiated study to examine whether early treatment of prehypertension, defined for this study as systolic blood pressure of 130 to 139 mmHg and diastolic pressure blood pressure of 89 mmHg or lower and systolic pressure of 139 mmHg or lower, might prevent or delay the development of subsequent incident hypertension. The primary objective of the present study was to determine whether in patients with prehypertension six months of treatment with an angiotensin II, type 1 receptor antagonist (at a dose of 8mg once a day) reduces the incidence of hypertension in borderline patients.

Page(s): 1-5

DOI: DOI not available

Published: Journal: Pakistan Journal of Pharmacology, Volume: 28, Issue: 2, Year: 2011

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views